Human CD8 and CD4 T cell epitopes of epithelial cancer antigens

Citation
N. Sato et al., Human CD8 and CD4 T cell epitopes of epithelial cancer antigens, CANC CHEMOT, 46, 2000, pp. S86-S90
Citations number
10
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN journal
03445704 → ACNP
Volume
46
Year of publication
2000
Supplement
S
Pages
S86 - S90
Database
ISI
SICI code
0344-5704(200006)46:<S86:HCACTC>2.0.ZU;2-B
Abstract
Recent human tumor immunology research has identified several genes coding immunogenic peptides recognized by CD8 cytotoxic T lymphocytes (CTLs) in me lanoma tumors. Very recently, CD4 T cell antigenic epitopes were also deter mined in certain melanoma tumors. The use of these peptides in conjunction with human immunotherapy could prove to be of great benefit. However, such peptides in clinically common tumors of epithelial cell origin, such as of the stomach, colon, lung, etc., have not yet been determined extensively. W e describe for the first time an HLA-A31 (A*31012)-restricted natural antig enic peptide recognized by the CD8 CTL TcHST-2 of gastric signet ring cell carcinoma cell line HST-2. We also identified the HLA-DRB1*08032-restricted peptide recognized by the CD4 T cell line TcOSC-20 of squamous cell carcin oma OSC-20 derived from the oral cavity. The antigenic peptide of HST-2, de signated F4.2, is composed of 10 amino acid residues with two anchor motif residues necessary for binding to HLA-A31 molecules. The synthetic F4.2 pep tide enhanced the reactivity of TcHST-2 against HST-2 cells. Furthermore, i ntroduction of an expression minigene coding F4.2 peptide to HLA-A31(+) cel ls conferred cytotoxic susceptibility to TcHST-2 on the cells. Some stomach cancer lines into which the HLA-A31 gene had been introduced, such as MKN2 8-A31-2, were lysed by TcHST-2, suggesting the presence of F4.2 peptide in at least some HLA-A31(+) stomach cancers. Furthermore, F4.2 peptide induced an F4.2 peptide-specific CTL response in at least 30-40% of HLA-A31(+) per ipheral blood lymphocytes from gastric cancer patients, suggesting that F4. 2 peptide could be used as a cancer vaccine for gastric tumors. The natural antigenic peptide of OSC-20 was also determined using acid extraction and biochemical separation and by mass spectrometry. Consequently, OSC-20 pepti de was designated as the 6-1-5 peptide, an HLA-DRB1*08032-restricted 16-mer peptide with two possible anchor motifs. It has an amino acid sequence ide ntical to that of human alpha-enolase, suggesting that it was derived from the processed parental alpha-enolase protein. We are presently attempting t o determine the genes that code tumor rejection antigens recognized by HLA- A24- and A26-restricted T cells, including those of pulmonary and pancreati c carcinomas. The search for these antigenic peptides may lead to the ident ification of immunogenic peptide antigens that would be suitable for clinic al use in commonly occurring epithelial cancers.